Update from our colleagues at the Alliance for Childhood Cancer (July 13, 2020): The House Appropriations Committee agreed to fully fund the Childhood Cancer STAR
On June 16, 2020, the Food and Drug Administration extended the indication of gemtuzumab ozogamicin (MYLOTARGTM, Wyeth Pharmaceuticals LLC) for newly-diagnosed CD33-positive acute myeloid leukemia
The American Association for Cancer Research (AACR) and the U.S. Food and Drug Administration (FDA) recorded a listening session on May 27, 2020 for patient
Day One Biopharmaceutical, a start-up biotech company founded with a focus on developing therapies for children with cancer through drug repurposing announced its debut in
CAC2 Members Jack’s Angels, Dragon Master Foundation, Max Cure Foundation, Children’s Cancer Cause, and National Brain Tumor Society joined together with others in the community
Thanks to the many-faceted efforts in the childhood cancer community, the STAR Act has reached a tipping point (173 co-sponsors in the House of Representatives as of March
The Congressional Childhood Cancer Caucus Presents Pediatric Cancer: Major Advances, Major Challenges 5th Annual Childhood Cancer Caucus Friday, September 19, 2014 9:00 – 10:30 a.m.
There will be a meeting next week at the National Cancer Institute (NCI) dedicated to pediatric cancer drug development. The National Cancer Institute (NCI) will
Link to Original on the Congressional Childhood Cancer Caucus website Nov 12, 2013 Caucus Asks Questions about the Ongoing Shortage of Daunorubicin WASHINGTON, D.C. – Out
